<DOC>
	<DOCNO>NCT02053727</DOCNO>
	<brief_summary>The purpose study investigate whether combination abatacept along entecavir ( study drug ) safe effective treating symptom relate rheumatoid arthritis ( RA ) . Abatacept , give intravenous ( IV - injected vein ) well subcutaneous form , approve FDA treatment RA . In research , abatacept give injection . A subcutaneous injection injection give skin . Entecavir , take mouth , approve FDA treatment hepatitis B . The study divide following time period : Screening Phase : Up 4 week Randomized Double-blind Phase : 24 week Open-label Extension Phase : 24 weeksFollow-up Phase : phone call Week 48 Each phase contain one study visit .</brief_summary>
	<brief_title>Abatacept v Placebo RA Patients With Hepatitis B Entecavir Background</brief_title>
	<detailed_description>Rheumatoid arthritis ( RA ) chronic , systemic inflammatory disorder affect 1 % world 's population . If adequately control , may lead disability 30 % patient within first three year disease onset [ 1 ] associated premature death . Recent research suggest first event pathogenesis RA antigen dependent activation T-cells immunogenetically susceptible host . T-cells require two signal activation , one involve trimolecular complex ( class II Major Histocompatibility Complex ( MHC ) , antigen , T-cell receptor ) , co-stimulation CD28 ( Cluster Differentiation 28 ) molecule T-cells B7 molecule ( CD80 CD86 ) antigen present cell . Hepatitis B virus ( HBV ) cause chronic disease 5 % immunocompetent adult prevalence 350 million worldwide . It lead cause chronic hepatitis , cirrhosis hepatocellular cancer account one million death annually . In patient chronic hepatitis B RA , treatment option limit . Traditional disease modify anti-rheumatic drug ( DMARDs ) associate hepatotoxicity contraindicate chronic hepatitis . A recent retrospective analysis suggest successful use anti-tumor necrosis factor alpha ( anti-TNF ) agent may possible patient author warn patient closely monitor fatal reactivation hepatitis B possible . Treatment rituximab , chimeric monoclonal antibody B-cell protein CD20 , another option ; however , use medication RA patient chronic hepatitis B may also cause reactivation . When RA patient chronic hepatitis B start Tumor Necrosis Factor ( TNF ) inhibitor methotrexate ( MTX ) , 2 5 HBsAg+ patient reactivate hepatitis B , indicate possible high rate activation patient hepatitis B treatment . Reactivation another study occur 9-19 month antirheumatic therapy . In RA patient chronic Hepatitis B , entecavir appear effective prevent reactivation . There study safety abatacept patient RA HBV . Adequate T-cell function important help cure contain HBV infection . Our site conduct retrospective study show preliminary safety abatacept patient RA chronic Hepatitis B antiviral therapy . The purpose study assess safety efficacy abatacept RA patient chronic Hepatitis B pilot study randomize , control fashion .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Diagnosis RA . 2 . Baseline CDAI &gt; 10 TJC ( Tender Joint Count ) &gt; 4 SJC ( Swollen Joint Count ) &gt; 2 . 3 . Chronic Hepatitis B define history patient HBsAg positive least 6 month undetectable HBV DNA ; history patient negative HBsAg positive HBcAb HBsAb , undetectable HBV DNA . 4 . No evidence hepatocellular carcinoma ( HCC ) base upon alphafetoprotein ( AFP ) ≤20 ng/mL screening , ) negative liver image show ultrasound , computerized tomography magnetic resonance imaging within 24 week screen . Participants AFP &gt; 20 ng/mL must evaluate clinically additional image show HCC CT MRI enrol . 5 . Oral corticosteroid ( ≤ 10 mg/day prednisone equivalent ) NSAIDs ( NonSteroidal Antiinflammatory Drugs ) permit patient stable dose regimen ≥ 2 week prior include baseline . 6 . Men woman , &gt; = 18 year age . 1 . Women pregnant breastfeeding . Sexually active fertile men use effective birth control partner WOCBP ( Women Child Bearing Potential ) . 2 . Target Disease Exceptions ) Rheumatic autoimmune disease RA ; fibromyalgia keratoconjunctivitis/xerostomia allow , long confound CLINICAL EFFICACY OUTCOMES . 3 . Medical History Concurrent Diseases 1 . Subjects impair , incapacitate , incapable completing studyrelated assessment . 2 . Subjects underwent previous MCP ( metacarpophalangeal ) arthroplasty , procedure schedule , anticipate need procedure study . 3 . Major surgery ( include joint surgery ) within 8 week prior screen 4 . Subjects active vasculitis major organ system , exception rheumatoid nodule minor rheumatoid vasculitis lesion skin 5 . Subjects current uncontrolled symptom severe , progressive , uncontrolled renal , hepatic hematologic , gastrointestinal , pulmonary , cardiac , neurologic , cerebral disease , include Cirrhosis ChildPugh Class &gt; =2 COPD ( chronic obstructive pulmonary disease ) FEV1 ( forced expiratory volume 1 second ) /FVC ( forced vital capacity ) &lt; 0.6 6 . Female subject recent breast cancer screen suspicious malignancy diagnosis exclude . h ) Subjects currently abuse drug alcohol . ) Subjects evidence active latent bacterial viral infection time potential enrollment , include HIV . j ) Subjects herpes zoster cytomegalovirus ( CMV ) resolve less 2 month inform consent document sign . k ) Subjects receive live vaccine within 3 month anticipate first dose study medication . l ) Subjects serious bacterial infection within last 3 month , unless treat resolved antibiotic , chronic bacterial infection . ) Subjects risk tuberculosis ( TB ) treat latent TB test positive . n ) Subjects positive hepatitis C antibody presence hepatitis C virus also show polymerase chain reaction recombinant immunoblot assay . ) Subjects abnormal laboratory value 4 . Prohibited Treatments and/or Therapies 1 . Subjects time receive treatment investigational drug within 28 day ( less 5 terminal halflives elimination ) Day 1 dose . 2 . Any concomitant biologic DMARD , anakinra . 3 . Previous treatment celldepleting therapy , include investigational agent , include limited CAMPATH , antiCD4 ( cluster differentiation 4 ) , antiCD5 , antiCD3 , antiCD19 . 4 . AntiCD20 treatment within last 6 month ( OK include dose &gt; 6 month ago ) . 5 . Treatment methotrexate , hydroxychloroquine , cyclosporine A , azathioprine , mycophenolate mofetil , within &lt; = 4 week prior baseline . 6 . Treatment etanercept within 2 week , infliximab/certolizumab/golimumab/adalimumab &lt; =8 week , anakinra within &lt; =1 week prior baseline . 7 . Previous abatacept use . 8 . Treatment sulfasalazine within &lt; 4 week prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Abatacept</keyword>
	<keyword>Orencia</keyword>
	<keyword>entecavir</keyword>
</DOC>